Literature DB >> 25641239

Progression of renal damage in glycogen storage disease type I is associated to hyperlipidemia: a multicenter prospective Italian study.

Daniela Melis1, Mariarosaria Cozzolino2, Giorgia Minopoli2, Francesca Balivo2, Rossella Parini3, Miriam Rigoldi3, Sabrina Paci4, Carlo Dionisi-Vici5, Alberto Burlina6, Generoso Andria2, Giancarlo Parenti2.   

Abstract

Angiotensin converting enzyme (ACE)-inhibitors decrease glomerular hyperfiltration but not microalbuminuria and proteinuria in glycogen storage disease type I. In the current study, we demonstrated that severe hyperlipidemia is associated with ACE-inhibitor ineffectiveness. We underline the importance of adequate metabolic control in glycogen storage disease type I. A combination therapy with ACE-inhibitors and lipid lowering drugs might be considered.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25641239     DOI: 10.1016/j.jpeds.2014.12.015

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  6 in total

1.  Tight metabolic control plus ACE inhibitor therapy improves GSD I nephropathy.

Authors:  Gyongyi O Okechuku; Lawrence R Shoemaker; Monika Dambska; Laurie M Brown; Justin Mathew; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2017-06-13       Impact factor: 4.982

2.  Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients.

Authors:  Roberta Resaz; Davide Cangelosi; Daniela Segalerba; Martina Morini; Paolo Uva; Maria Carla Bosco; Giuseppe Banderali; Ana Estrella; Corbinian Wanner; David A Weinstein; Annalisa Sechi; Sabrina Paci; Daniela Melis; Maja Di Rocco; Young Mok Lee; Alessandra Eva
Journal:  Int J Mol Sci       Date:  2021-12-28       Impact factor: 5.923

3.  Glycogen storage disease type 1a in the Ohio Amish.

Authors:  Ethan M Scott; Olivia K Wenger; Elizabeth Robinson; Kristina Colling; Miraides F Brown; Jennifer Hershberger; Kadakkal Radhakrishnan
Journal:  JIMD Rep       Date:  2022-06-21

4.  A preliminary study of telemedicine for patients with hepatic glycogen storage disease and their healthcare providers: from bedside to home site monitoring.

Authors:  Irene J Hoogeveen; Fabian Peeks; Foekje de Boer; Charlotte M A Lubout; Tom J de Koning; Sebastiaan Te Boekhorst; Robert-Jan Zandvoort; Rob Burghard; Francjan J van Spronsen; Terry G J Derks
Journal:  J Inherit Metab Dis       Date:  2018-03-29       Impact factor: 4.982

5.  Over 20-Year Follow-up of Patients with Hepatic Glycogen Storage Diseases: Single-Center Experience.

Authors:  Edyta Szymańska; Patryk Lipiński; Dariusz Rokicki; Janusz Książyk; Anna Tylki-Szymańska
Journal:  Diagnostics (Basel)       Date:  2020-05-13

6.  Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report.

Authors:  Alessandro Rossi; Erasmo Miele; Simona Fecarotta; Maria Veiga-da-Cunha; Massimo Martinelli; Carmine Mollica; Maria D'Armiento; Enza Mozzillo; Pietro Strisciuglio; Terry G J Derks; Annamaria Staiano; Giancarlo Parenti
Journal:  Ital J Pediatr       Date:  2021-07-02       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.